Precigen (PGEN) Expected to Post Quarterly Earnings on Tuesday

Precigen (NASDAQ:PGEN) is expected to release its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Precigen to post earnings of ($0.0121) per share and revenue of $27.9810 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Precigen (NASDAQ:PGEN) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The company had revenue of $23.25 million for the quarter, compared to the consensus estimate of $20.81 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%. On average, analysts expect Precigen to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Precigen Trading Up 5.6%

Precigen stock opened at $6.27 on Friday. The business has a 50-day simple moving average of $4.98 and a two-hundred day simple moving average of $4.41. The company has a market cap of $2.24 billion, a P/E ratio of -5.31 and a beta of 1.00. Precigen has a 52-week low of $1.63 and a 52-week high of $6.28. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62.

Insider Buying and Selling

In related news, CEO Helen Sabzevari sold 346,836 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the completion of the transaction, the chief executive officer directly owned 3,768,872 shares in the company, valued at approximately $22,198,656.08. The trade was a 8.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Harry Jr. Thomasian sold 171,429 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $5.53, for a total transaction of $948,002.37. Following the completion of the sale, the chief financial officer directly owned 354,535 shares of the company’s stock, valued at $1,960,578.55. This represents a 32.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 922,728 shares of company stock valued at $5,028,853 in the last 90 days. Corporate insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

Hedge funds and other institutional investors have recently modified their holdings of the company. CANADA LIFE ASSURANCE Co purchased a new position in shares of Precigen during the 4th quarter valued at $85,000. Daiwa Securities Group Inc. increased its stake in Precigen by 2,762.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 20,265 shares of the biotechnology company’s stock worth $85,000 after buying an additional 19,557 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in Precigen in the 3rd quarter worth $75,000. Strs Ohio purchased a new stake in Precigen in the 1st quarter worth $70,000. Finally, BNP Paribas Financial Markets raised its holdings in Precigen by 134.7% during the second quarter. BNP Paribas Financial Markets now owns 48,803 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 28,005 shares during the period. 33.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PGEN. Citigroup reiterated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Citizens Jmp boosted their target price on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. HC Wainwright increased their price target on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Finally, Wall Street Zen cut shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $12.50.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.